Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Savannah, GA
NPI
1619191103
Since 2007
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6602 Waters Ave, Building C
Savannah, GA, 31406
Phone (912) 354-7676
Groups this clinician bills Medicare through
Medicare paid, 2024
$600K
74,609 services
Medicare patients, 2024
154
Average age 68
Drug cost, 2024
$227K
1,076 prescriptions
Company payments, 2025
$8,109
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Katherine M Moretz was code J0174 (injection, lecanemab-irmb, 1 mg), 54,300 times for 26 patients. In total Katherine M Moretz billed 74,609 services in 38 codes, and Medicare paid $600K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 54,300 | 26 | $1.05 | $57K |
| J3032 Injection, eptinezumab-jjmr, 1 mg | Office | 10,500 | 29 | $14.13 | $148K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 139 | 64 | $0.51 | $71.54 |
| 96413 Chemotherapy Administration | Office | 98 | 39 | $90.69 | $8,888 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 65 | 62 | $9.75 | $634 |
| 96365 Intravenous Infusion, Hydration | Office | 61 | 36 | $44.11 | $2,691 |
| 99214 Office E&M - Established | Office | 38 | 37 | $70.35 | $2,673 |
| 99213 Office E&M - Established | Office | 36 | 35 | $47.96 | $1,727 |
By year: 2022 $529K for 19,418 services; 2023 $812K for 36,295 services; 2024 $600K for 74,609 services.
Medicare prescription drug claims, 2024
In 2024, the drug Katherine M Moretz prescribed most often to Medicare patients was Levetiracetam, with 149 prescriptions and refills. In total Katherine M Moretz wrote 1,076 Medicare prescriptions that cost $227K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 149 | 226 | 29 | $4,346 |
| Lamotrigine Generic | 100 | 120 | 11 | $2,705 |
| Baclofen Generic | 73 | 95 | 12 | $1,710 |
| Clonidine Hcl Generic | 54 | 76 | Under 11 | $179 |
| Topiramate Generic | 51 | 98 | 14 | $736 |
| Trazodone Hcl Generic | 37 | 47 | Under 11 | $172 |
| Scopolamine Generic | 34 | 34 | Under 11 | $3,588 |
| Risperidone Generic | 34 | 42 | Under 11 | $1,175 |
| Amitriptyline Hcl Generic | 26 | 48 | Under 11 | $514 |
| Lorazepam Generic | 24 | 24 | Under 11 | $49.71 |
| Oxcarbazepine Generic | 20 | 22 | Under 11 | $4,610 |
| Sertraline Hcl Generic | 20 | 20 | Under 11 | $1,913 |
| Lacosamide Generic | 19 | 27 | Under 11 | $1,935 |
| Pregabalin Generic | 18 | 18 | Under 11 | $79.79 |
| Clobazam Generic | 18 | 18 | Under 11 | $2,115 |
Brand drugs: 92 claims; generic drugs: 984 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Katherine M Moretz $8,109 ($8,109 in general payments such as food, travel and fees) from 32 companies. The largest payer was UCB, Inc. with $4,046.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 22 | $4,046 |
| Jazz Pharmaceuticals Inc. JAZZ | 12 | $1,974 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $243 |
| Abbvie Inc. ABBV | 10 | $192 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $150 |
| Argenx US, Inc. ARGX | 4 | $109 |
| Neurelis, Inc. | 4 | $95.83 |
| LivaNova USA, Inc. LIVN | 1 | $92.93 |
| Teva Pharmaceuticals USA, Inc. TEVA | 5 | $89.58 |
| Biogen, Inc. BIIB | 4 | $89.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.